StonvexLoading…
StonvexStonvexStonvexCore line items from RCAT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2024 2024-04-30 | Annual 2023 2023-04-30 |
|---|---|---|---|---|
Revenue | $40.73M | $4.85M | $17.84M | $1.31M |
Operating Income | $-66.60M | $-25.84M | $-19.30M | $-26.34M |
Net Income | $-72.08M | $-43.61M | $-24.05M | $-28.11M |
EPS (Diluted) | $-0.73 | $-0.57 | $-0.40 | $-0.52 |
Total Assets | $273.68M | $55.60M | $48.54M | $60.74M |
Total Liabilities | $27.84M | $5.49M | $4.97M | $5.98M |
Cash & Equivalents | $167.87M | $9.15M | $6.07M | $3.17M |
Free Cash Flow OCF − CapEx | $-95.78M | $-20.70M | $-17.98M | $-31.65M |
Shares Outstanding | 120.07M | 85.22M | 74.29M | 54.57M |